ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines

ReCode Therapeutics continues to evolve and expand its strategy for delivering genetic medicines with its novel selective organ targeting (SORT) lipid nanoparticle (LNP) technology, enabled by its latest financing, a $120m extension of its series B venture capital round that brings the total to $200m. The company plans to broaden the types of payloads its SORT LNPs can deliver and expand its pipeline beyond its two lead programs, which will begin clinical trials in 2023.

Menlo Park, CA-based ReCode merged with TranscripTx and raised an $80m series A round in March 2020 to develop RNA therapeutics and other genetic medicines with its LNP technology and to advance its two respiratory programs toward the clinic. (Also see "ReCode Combines With TranscripTx, Raises $80m For Novel RNA Drugs" - Scrip, 26 March, 2020.) ReCode then closed on the initial $80m of its series B round in October 2021 to fund the first clinical trials for its lead programs in primary ciliary dyskinesia and cystic fibrosis, expand its R&D pipeline to additional genetic respiratory diseases, and further advance its LNP platform and manufacturing capabilities